Shexiang Tongxin Dropping Pill Attenuates Atherosclerotic Lesions in ApoE Deficient Mouse Model.

Minqi Xiong,Chenglin Jia,Jingang Cui,Peiwei Wang,Xiaoye Du,Qinbo Yang,Yuling Zhu,Wenjian Wang,Teng Zhang,Yu Chen
DOI: https://doi.org/10.1016/j.jep.2014.11.013
IF: 5.195
2014-01-01
Journal of Ethnopharmacology
Abstract:Ethnopharmacological relevance: Shexiang Tongxin dropping pill (STDP) is a formulation of Traditional Chinese Medicine mainly used for clinical treatment of stable angina pectoris in China.Aim of the study: To investigate the effects and mechanisms of STOP treatment on atherosclerosis.Materials and methods: ApoE deficient (ApoE(-/-)) mice were utilized to evaluate the effect of STDP treatment (30 mg/kg/day) on atherosclerotic lesions. Histopathological features of atherosclerotic lesions, serum levels of lipid proteins, parameters of oxidative stress and pro-inflammatory cytokines were measured by H&E staining, Masson's trichrome staining and ELISA, respectively. Real-time PCR analyses were performed to examine the aortic expression of atherosclerosis-associated microRNAs.Results: The STDP treatment resulted in attenuated atherosclerotic lesion manifested by reduced lipid deposition, fibrosis and oxidative stress. It also led to increase in serum levels of GSH and SOD, decrease in MDA, decrease in CHO, TG, LDL, ox-LDL and increase in HDL, respectively. Additionally, the levels of pro-inflammatory cytokines including IL-2, IL-6, TNF-alpha and gamma-IFN were markedly reduced by STOP treatment. Furthermore, STDP treatment was associated with a significant reduction in the aortic expression of miR-21a, miR-132, miR-126a, miR-155 and increased expression of miR-20a.Conclusion: Our results demonstrated for the first time that STOP attenuated atherosclerotic lesions in ApoE-/- mouse model. Moreover, STDP treatment exhibited multi-targeting effects on pathological, biochemical and molecular aspects of atherosclerosis implicating lipid regulation, fibrosis, inflammation and oxidative stress. Findings from the current study warrant further evaluation of the clinical application of STOP in atherosclerosis treatment. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
What problem does this paper attempt to address?